Prevalence of the mutational pattern E44D/A and/or V118I in the reverse transcriptase (RT) gene of HIV-1 in relation to treatment with nucleoside analogue RT inhibitors

Journal of Medical Virology

Volumn 66, Issue 3, 2002, Pages 299-303

  Montes, Brigitte ^a   Segondy, Michel ^a,b  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b Laboratoire de Virologie   (France)

Author keywords

Genotype; Nucleoside analogue reverse transcriptase inhibitors; Resistance

Indexed keywords

ABACAVIR; DIDANOSINE; GENE PRODUCT; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; THYMIDINE DERIVATIVE; VIRUS ENZYME; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CODON; CORRELATION ANALYSIS; FEMALE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREVALENCE; SEQUENCE ANALYSIS; VIRUS GENE; VIRUS MUTATION; VIRUS VIRULENCE;

ANTI-HIV AGENTS; DEOXYRIBONUCLEOSIDES; GENES, VIRAL; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTAGENESIS; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0036154902     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.2145     Document Type: Article

References (18)

1. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
2. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine
3. Prevalence and conditions of selection of E44D/A and V118I human immunodeficiency virus type 1 reverse transcriptase mutations in clinical practice
4. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′,3′-dideoxycytidine
5. Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase abacavir (1592U89) after monotherapy and combination therapy
6. A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V
7. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine
8. Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance
9. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2′,3′-dideoxythymidine in cell culture
10. Analysis of clinical isolates and site-directed mutants reveals the genetic determinants of didanosine resistance
11. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)
12. Use of neural networks to define the genetic basis of HIV-1 resistance to d4T
13. A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance
14. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy
15. Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1 infected patients with failure of highly active antiretroviral therapy
16. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleotides in patients receiving therapy with dideoxynucleosides
17. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase
18. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase